Hear Again Franchising

Item 7 details the initial investment from $187,100 to $318,450, including a $50,000 franchise fee, driven by build-out, inventory, and training costs. Ongoing fees hit 5% royalty, plus $500 monthly technology and $100 software fees, with no current brand fund but potential up to 3%. Item 19 reports average gross revenue of $399,221 across units, yet EBITDA margin sits at 0%, translating to estimated profits of $15,969 to $83,836—modest returns that demand high volume in a market crowded by clinics and online sellers. These figures reflect a 2025 FDD for a system just two years into franchising.

Growth stands at +12% from 33 to 37 locations last year (33 corporate, only 4 franchised), with 11 new units projected, signaling optimism but caution given the lopsided corporate dominance. Two SBA loans average $340,750, above typical service franchise sizes, hinting at capital-intensive startups. For investors, the low franchise count means limited peer data, but Item 19 transparency and steady expansion suggest potential if you can hit revenue targets amid FDA rules and competition—though zero EBITDA flags thin margins requiring operational efficiency.